Ruxolitinib(CAS: 941678-49-5)

Ruxolitinib is a Janus kinase (JAK) inhibitor with the chemical formula C21H22N4O2S. It is a white to off-white powder that is soluble in DMSO and dimethylformamide. Ruxolitinib is known for its ability to modulate immune responses and is widely used in the treatment of certain hematological malignancies and autoimmune diseases.

Ruxolitinib is primarily used in the treatment of myelofibrosis, polycythemia vera, and other blood disorders. It also finds applications in research for studying inflammatory and autoimmune conditions. Additionally, it is used in pharmaceutical formulations for its immunomodulatory properties and in clinical trials for various diseases.

Ruxolitinib is generally considered safe when used as directed, but it may cause side effects such as infections, anemia, and thrombocytopenia. Proper handling and use under medical supervision are essential. Safety standards include adherence to guidelines for pharmaceutical use and appropriate storage conditions to maintain its efficacy and safety.

Ruxolitinib should be stored in a cool, dry place away from direct light. It is typically kept at a temperature between 15°C to 25°C and in airtight containers to prevent moisture exposure. Proper storage ensures stability and maintains the compound's therapeutic effectiveness.